144 related articles for article (PubMed ID: 11296618)
21. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
22. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Fountzilas G; Dafni U; Gogas H; Linardou H; Kalofonos HP; Briasoulis E; Pectasides D; Samantas E; Bafaloukos D; Stathopoulos GP; Karina M; Papadimitriou C; Skarlos D; Pisanidis N; Papakostas P; Markopoulos C; Tzorakoeleftherakis E; Dimitrakakis K; Makrantonakis P; Xiros N; Polichronis A; Varthalitis I; Karanikiotis C; Dimopoulos AM;
Ann Oncol; 2008 May; 19(5):853-60. PubMed ID: 18042835
[TBL] [Abstract][Full Text] [Related]
23. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
[TBL] [Abstract][Full Text] [Related]
24. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
25. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Lisboa BW; Untch M; Kühnle H; Jänicke F; Meerpohl HG; Lindner C; Konecny G; Hecker D; Diergarten K
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
[TBL] [Abstract][Full Text] [Related]
26. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
[TBL] [Abstract][Full Text] [Related]
27. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
28. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
30. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
31. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Rossi D; Graziano F; Luzi Fedeli S; Fedeli A; Alessandroni P; Catalano V; Giordani P; Testa E; Catalano G
Minerva Med; 2002 Aug; 93(4):303-7. PubMed ID: 12207200
[TBL] [Abstract][Full Text] [Related]
34. First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Dimopoulos AM; Papadimitriou C; Kalogera-Fountzila A; Aravantinos G; Bafaloukos D; Athanassiades A; Nicolaides C; Keramopoulos A; Pavlidis N; Kosmidis P; Skarlos D
Ann Oncol; 1998 Sep; 9(9):1031-4. PubMed ID: 9818080
[TBL] [Abstract][Full Text] [Related]
35. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
[TBL] [Abstract][Full Text] [Related]
36. A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
Erman M; Baltali E; Karaoglu A; Abali H; Engin H; Ozisik Y; Guler N; Altundag K; Tekuzman G; Atahan IL; Onat D; Sayek I
Cancer Invest; 2005; 23(3):215-21. PubMed ID: 15945507
[TBL] [Abstract][Full Text] [Related]
37. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
38. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in local-regionally advanced breast cancer: a preliminary report.
Baltali E; Altundağ MK; Onat DA; Abbasoğlu O; Ozişik Y; Güler N; Atahan L; Berberoğlu U; Altinok M; Baran I; Celik I; Tekuzman G
Tumori; 2002; 88(6):474-7. PubMed ID: 12597141
[TBL] [Abstract][Full Text] [Related]
40. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
Mavroudis D; Alexopoulos A; Ziras N; Malamos N; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Tsavaris N; Potamianou A; Rigatos G; Georgoulias V
Ann Oncol; 2000 Oct; 11(10):1249-54. PubMed ID: 11106112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]